Sana Ghalib, MD
Pulmonary Disease · Ashland, KYNPI 1023460441
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 48.8% of the total. 2025 is the largest year on record at $9,320, more than ten times the $440 reported in 2021.
Across 297 payments — averaging $53.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- GSK$2K
- AstraZeneca$1K
- Sanofi$729
- Grifols USA, LLC$544
- Regeneron Healthcare Solutions, Inc.$375
- plus $3K from 25 others
What the payments were for
- Travel & lodging$4553%
- Food & beverage$8,45053%
- Education$7,04544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $7,781 |
| GSK | 93 | $2,305 |
| AstraZeneca | 23 | $1,081 |
| Sanofi | 13 | $729 |
| Grifols USA, LLC | 22 | $544 |
| Regeneron Healthcare Solutions, Inc. | 11 | $375 |
| Genentech USA, Inc. | 23 | $359 |
| Pulmonx Corporation | 8 | $312 |
| Mylan Specialty L.p. | 11 | $299 |
| Boehringer Ingelheim | 12 | $253 |
| Actelion Pharmaceuticals US, Inc. | 2 | $230 |
| United Therapeutics Corporation | 12 | $222 |
| Electromed, Inc. | 12 | $218 |
| Viatris Specialty LLC | 5 | $138 |
| Merck | 2 | $132 |
| Amgen | 4 | $128 |
| Novartis | 6 | $121 |
| Verona Pharma, Inc. | 3 | $119 |
| Genentech, Inc. | 1 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $95 |
| Baxter Healthcare | 3 | $82 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| ERBE USA Inc | 1 | $50 |
| Astellas Pharma US Inc | 1 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,950 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 55 | $713,487 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 280 | $239,624 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 82 | $52,718 |
| Dupixent SyringeDupilumab | 11 | $41,113 |
| Tadalafil | 15 | $34,041 |
| Spiriva HandihalerTiotropium Bromide | 20 | $18,647 |
| Spiriva RespimatTiotropium Bromide | 16 | $12,242 |
| EliquisApixaban | 12 | $8,871 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $8,148 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,208 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,447 |
| Tiotropium Bromide | 11 | $6,218 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,800 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $5,731 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $2,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $253 | $732,93682 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,305 | $246,071292 claims |
| AstraZenecaBreztri Aerosphere | $1,081 | $52,71882 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Ashland
- Sabrina RobertsAshland$15K
- Scott NelsonAshland$12K
- Mena ShehataAshland$11K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.